公开(公告)号：KR1020080035378A

公开(公告)日：2008-04-23

申请号：KR1020060102010

申请日：2006-10-19

Applicant: (주)아모레퍼시픽 ,  재단법인서울대학교산학협력재단

Inventor： 신의석 ,  이태룡 ,  조시영 ,  신동욱 ,  김재범 ,  박지영

IPC: A61K31/047 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10

Abstract: A composition for inhibiting the activity of glucose-6-phosphate dehydrogenase is provided to inhibit production of NADPH(nicotinamide adenine dinucleotide phosphate) and fat biosynthesis, so that the composition is useful for prevention and treatment of fat metabolism disorders including obesity, hyperlipidemia and diabetes. A composition for inhibiting the activity of glucose-6-phosphate dehydrogenase comprises the compounds represented by the formula(1) selected from epigallocatechin gallate, gallocatechin gallate, epicatechin gallate, catechin gallate, octyl gallate and lauryl gallate, wherein R^1 is H or OH, R^2 is a structural formula 1 or 2, R^3 is C3-C20 alkyl, X is a structural formula 3 or 4, and R^4 is H or a structural formula 5; and the compounds represented by the formula(1) is quercetin or myricetin.

Abstract translation: 提供用于抑制葡萄糖-6-磷酸脱氢酶活性的组合物以抑制NADPH（烟酰胺腺嘌呤二核苷酸磷酸酯）的产生和脂肪生物合成，使得该组合物可用于预防和治疗脂肪代谢障碍，包括肥胖症，高脂血症和糖尿病 。 用于抑制葡萄糖-6-磷酸脱氢酶活性的组合物包括选自表没食子儿茶素没食子酸酯，没食子儿茶素没食子酸酯，表儿茶素没食子酸酯，儿茶素没食子酸酯，没食子酸辛酯和没食子酸月桂酯的式（1）表示的化合物，其中R 1是H或 OH，R 2是结构式1或2，R 3是C 3 -C 20烷基，X是结构式3或4，R 4是H或结构式5; 由式（1）表示的化合物是槲皮素或杨梅素。

公开(公告)号：KR1020090015059A

公开(公告)日：2009-02-11

申请号：KR1020087027541

申请日：2006-04-10

Applicant: 재단법인서울대학교산학협력재단

Inventor： 김재범 ,  박지영

IPC: A61K48/00 ,  C12N15/10 ,  A61P29/00

Abstract: A pharmaceutical composition comprising G6PD is provided to reduce the oxidative stress and inflammation which are closely related to metabolic disorder such as insulin resistance, type 2 diabetes, cardiovascular diseases and arteriosclerosis. The pharmaceutical composition for preventing and treating disease associated with oxidative stress and inflammation comprises G6PD(glucose-6-phosphate dehydrogenase) or its expression inhibitor such as dehydroepiandrosterone(DHEA) or its derivatives, which is selected from SEQ ID NO:1 to 6, preferably siRNA(small interfering RNA) of SEQ ID NO:5 or 6.

Abstract translation: 提供包含G6PD的药物组合物以减少与代谢紊乱如胰岛素抵抗，2型糖尿病，心血管疾病和动脉硬化密切相关的氧化应激和炎症。 用于预防和治疗与氧化应激和炎症相关的疾病的药物组合物包含选自SEQ ID NO：1至6的G6PD（葡萄糖-6-磷酸脱氢酶）或其表达抑制剂如脱氢表雄酮（DHEA）或其衍生物， 优选SEQ ID NO：5或6的siRNA（小干扰RNA）。